Vitrolife: The company enters 2023 with good progress - Redeye

Vitrolife’s enters 2023 with good progress. The organic growth is 9%, with support from all three lines of business. It is also reassuring that Genetic Services delivers a quarter with 7% organic growth. The gross margin is an important value driver, and the 56.7% gross margin is also a decisive outcome. The overall result is ahead of both our and the market expectations, and we expect a distinctive 5%+ positive share price reaction on the back of Vitrolife’s Q1. Our base case valuation ahead of Q1 was SEK285 and a Bull Case of SEK400 and a Bear Case of SEK140.

Länk till analysen i sin helhet: https://www.redeye.se/research/895988/vitrolife-the-company-enters-2023-with-good-progress?utm_source=finwire&utm_medium=RSS